What's new in Guillain-Barré syndrome?

Practical Neurology

Volumn 6, Issue 4, 2006, Pages 208-217

  Pritchard, Jane ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CALPAIN; CARBAMAZEPINE; COMPLEMENT INHIBITOR; CORTICOSTEROID; GABAPENTIN; GANGLIOSIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; RITUXIMAB; VACCINE;

AREFLEXIA; ATAXIA; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG USE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTION; NERVE FIBER DEGENERATION; OPHTHALMOPLEGIA; PARANEOPLASTIC SYNDROME; PATIENT CARE; PATIENT EDUCATION; RECURRENT DISEASE; REVIEW;

EID: 33746743686     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2006.097709     Document Type: Review

References (40)

1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl);S21-S24.
2. Hadden RDM, Cornblath DR, Hughes RAC, et al and the Plasma exchange/ Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998;44;780-8.
3. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109;1115-26.
4. McKhann GM, Cornblath DR, Ho TW, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-7.
5. Lo YL, Chan LL, Pan A, et al. Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi. J Neurol Neurosurg Psychiatry 2004;75:436-40.
6. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-15.
7. Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-65.
8. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China, Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
9. Rees JH, Soudain SE, Gregson NA, et al. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995a;333:1374-9.
10. Visser LH, van der Meche FG, Meulstee J et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996;47:668-73.
11. Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995;38:218-24.
12. Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984;119:841-79.
13. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
14. Solomon T, Willison H. Infectious causes of acute flaccid paralysis. Curr Opin Infect Dis 2003;16:375-81.
15. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-66.
16. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125:2591-625.
17. Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9.
18. Odaka M, Yuki N, Yamada M, et al. Bickerstaffs brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003;126:2279-90.
19. Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45:168-73.
20. Kusunoki S, Chiba A, Kon K, et al. Nacetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994;35:570-6.
21. Rees JH, Gregson NA, Hughes RAC, et al. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995c;38:809-16.
22. Ogawara K, Kuwabara S, Koga M, et al. Anti-GM1b IgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection. J Neurol Sci 2003;210:41-5.
23. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-20.
24. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA 2004;101:11404-9.
25. Gong Y, Tagawa Y, Lunn MP, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002;125:2491-506.
26. Miyazaki T, Kusunoki S, Kaida K, et al. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology 2001;56:1227-9.
27. Kusunoki S, Shimizu J, Chiba A, et al. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996;39:424-31.
28. Kusunoki S, Hitoshi S, Kaida K, et al. Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. Neurosci Lett 1999;273:33-6.
29. Rees JH, Vaughan RW, Kondeatis E, et al. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 1995b;62:53-7.
30. Magira EE, Papaioakim M, Nachamkin I, et al. Differential distribution of HLA-DQ β/DR β epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ β epitopes associated with susceptibility to and protection from AIDP. J Immunol 2003;170:3074-80.
31. Malandrini A, Villanova M, Dotti MT, et al. Acute inflammatory neuropathy in Charcot-Marie-Tooth disease. Neurology 1999;52:859-61.
32. Raphael JC, Chevret S, Hughes RAC, et al. Plasma exchange for Guillain-Barré syndrome (Cochrane Review). The Cochrane Database of Systematic Reviews 2002, Issue 2. Art No: CD001798. DOI: 10.1002/ 14651858.CD001798. Chichester, UK: John Wiley εt Sons, Ltd.
33. Hughes RAC, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barré syndrome The Cochrane Database of Systematic Reviews 2006, Issue 1. Art No: CD002063. DOI: 10.1002/14651858. CD002063.pub3. Chichester, UK: John Wiley εt Sons, Ltd.
34. Hughes RAC, van der Meché FGA. Corticosteroids for Guillain-Barré syndrome. The Cochrane Database of Systematic Reviews 2000, Issue 2. Art No: CD001446. DOI: 10.1002/14651858.CD001446. Chichester, UK: John Wiley εt Sons, Ltd.
35. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:792-6.
36. Garssen MP, Schmitz PI, Merkies IS, et al. Amantadine for treatment of fatigue in Guillain-Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry 2006;77:61-5.
37. White CM, Pritchard J, Turner Stokes L. Exercise for people with peripheral neuropathy The Cochrane Database of Systematic Reviews 2004, Issue 4. Art No: CD003904. DOI: 10.1002/14651858.CD003904.pub2. Chichester, UK: John Wiley εt Sons, Ltd.
38. Garssen MP, Bussmann JB, Schmitz PI, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology 2004;63:2393-5.
39. Pritchard J, Mukherjee R, Hughes RAC. Risk of relapse of Guillain-Barré Syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurasurg Psychiatry 2002;73:348-9.
40. Willison HJ, Townson K, Veitch J, et al. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera Brain 2004;127:680-91.